Results 151 to 160 of about 880,981 (299)

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

British Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra, Luiza B. Negreiros, Amaury Pereira‐Acácio, Isadora G. Almeida, João P. M. Veloso‐Santos, Jarlene A. Lopes, Glória Costa‐Sarmento, Humberto Muzi‐Filho, Adalberto Vieyra   +8 more
wiley   +1 more source

The Prevalence of Variations in the Morphology of Renal Arteries in the North Indian Population. [PDF]

Cureus
Bashri R, Singh R.
europepmc   +1 more source

Causality assessment tool for drug‐induced acute kidney injury in patients admitted to intensive care units: Requirements from a multicentre retrospective study in the Netherlands reusing data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to provide key requirements for a drug‐induced acute kidney injury (d‐AKI) causality assessment tool (CAT) for intensive care unit (ICU) patients, using vancomycin‐induced AKI (v‐AKI) as a test case. Methods A retrospective review was conducted by medical experts of electronic health records of ICU patients from 14 Dutch ICUs.
Joanna E. Klopotowska, Izak A. R. Yasrebi‐de Kom, Nicolette F. de Keizer, Dave A. Dongelmans, on behalf of the RESCUE Study group, Merijn C. Reuland, Irma M. Rigter, Peter F. Schutte, Ilona T. Spaan, Dorieke van Balen, Stefaan Hendriks, Petronella E. Deetman, Cedric Lau, Wytze J. Vermeijden, Marieke G. J. Schouten, Joost B. Masselink, Peter E. Spronk, Marnix Kuindersma, Hendrikus J. M. van Kan, Anne Wellink, Abraham J. Valkenburg, Andre Wieringa, Walter M. van den Bergh, Maurits H. Renes, Wouter Bult, Frouke M. Engelaer, Nienke van Rein, Martijn Hoeksema, Janneke M. van den Broek, Elsbeth Wesselink, Ilse M. Purmer, Thomas Ottens, Bertha E. Bosma, Sjoerd H. W. van Bree, Barbara Festen, Hendrick J. W. Lammers, Rob J. Bosman, Rogier M. Determann, Eric J. F. Franssen, Attila Karakus, Lenneke. E. M. Haas, Freek van Gorp, Dylan W. de Lange, Maaike A. Sikma, Esther V. Uijtendaal   +44 more
wiley   +1 more source

Case Report: Dual embolism of the pulmonary and renal arteries after laparoscopy. [PDF]

Front Med (Lausanne)
Yang Z, Li Y, Wang X, Xu B, Xu X, Huang X.   +5 more
europepmc   +1 more source

Accessory renal arteries - a source of hypertension: A case report. [PDF]

World J Clin Cases, 2023
Calinoiu A, Guluta EC, Rusu A, Minca A, Minca D, Tomescu L, Gheorghita V, Minca DG, Negreanu L.   +8 more
europepmc   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

EBDE clearing: A strategy for simultaneous 3D visualization and quantitative analysis of both renal arteries and glomeruli. [PDF]

Theranostics
Wu Y, Shen Q, Liang Y, Bai L, Wu J, Shi Q, Wu L, Wang M, Liu Y, Huang K.   +9 more
europepmc   +1 more source

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension

British Journal of Clinical Pharmacology, EarlyView.
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien, Burabha Pussadhamma, Sirimas Kanjanawart, Thikhumporn Areesinpitak, Nontaya Nakkam, Chingching Foocharoen, Wichittra Tassaneeyakul, Suda Vannaprasaht   +7 more
wiley   +1 more source

Wunderlich syndrome in a hypertensive male with multiple renal arteries: a rare case report. [PDF]

Int J Surg Case Rep
Karki G, Lamsal S, Karki G.
europepmc   +1 more source